The objective of future treatment for retinoblastoma in children is to improve eye salvage rates. Dr Jesse Berry (Children’s Hospital Los Angeles, University of Southern California, Keck School of Medicine, CA, USA) talks about the current treatment landscape for this disease.
The presentation, ‘Tall dark and uh-oh: an ocular oncology update’ was presented at Hawaiian Eye and Retina meeting, 14-20 January 2023.
Questions:
- Could you please give us a brief overview of retinoblastoma in children? (0:21)
- What are the challenges in treating this disease in children? (1:35)
- What do you predict will be important for improving prognosis for eye salvage in the future? (2:38)
- What are the key take-home messages from your presentation? (4:03)
Disclosures: Jesse Berry is a consultant to Immunocore (5/2019), Castle Biosciences (12/2020) and Biotissue (5/2021); has received grant/research support from National Cancer Institute of the National Institute of Health Award Number K08CA232344 The Wright Foundation Children’s Oncology Group/St. Baldrick’s Foundation, Danhakl Family Foundation, The Knights Templar Eye Foundation, Research to Prevent Blindness Medical Student Eye Research Fellowship (Recipient: Shreya Sirivolu, Mentor: Jesse Berry) Hyundai Hope on Wheels Childhood Eye Cancer Trust Children’s Cancer Research Fund, A. Linn Murphree, MD, Chair in Ocular Oncology, The Berle & Lucy Adams Chair in Cancer Research The Larry and Celia Moh Foundation The Institute for Families, Inc. and Children’s Hospital Los Angeles; and royalties from Elsevier & Springer Provisional Patent Aqueous humor cell free DNA for diagnostic and Prognostic evaluation of Ophthalmic Disease 62/654,160 (Berry, Xu, Hicks), DNA methylation signature of Retinoblastoma 63/375,511 (Berry, Xu, Liang, Li).
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Lisa Glass.
Filmed as a highlight of Hawaiian Eye
Access more content on Ocular Oncology here
